Showing results (1401-1410 of 1,518) with videos related to
Sort By:
Pageof 152
ESMO Open|January 21, 2020
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapyEdward B Garon, Giorgio Vittorio Scagliotti, Oliver Gautschi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 9, 2025
Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) ImmunotherapyMarcel Wiesweg, Ali Alaffas, Anna Rasokat, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2016
Clinicopathologic Features of Advanced Squamous NSCLCMark A Socinski, Coleman Obasaju, David Gandara, et al.Future Oncology (London, England)|April 6, 2026
SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in <i>KRAS</i> G12C NSCLCSolange Peters, Maximilian Hochmair, Kathryn C Arbour, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 24, 2021
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189D Rodríguez-Abreu, S F Powell, M J Hochmair, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2023
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 StudyMarina C Garassino, Shirish Gadgeel, Giovanna Speranza, et al.Virchows Archiv : an International Journal of Pathology|October 8, 2024
TTF-1 is a highly sensitive but not fully specific marker for pulmonary and thyroidal cancer: a tissue microarray study evaluating more than 17,000 tumors from 152 different tumor entitiesKatharina Möller, Tayyaba Gulzar, Maximilian Lennartz, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2024
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLCKazuhiko Nakagawa, Edward B Garon, Takashi Seto, et al.JAMA Oncology|September 2, 2021
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical TrialLeora Horn, Ziping Wang, Gang Wu, et al.Nature Metabolism|July 21, 2025
LONP1 regulation of mitochondrial protein folding provides insight into beta cell failure in type 2 diabetesJin Li, Yamei Deng, Marie Gasser, et al.Pageof 152